Opinions
James Hodgins
Neptune Tech & Bioresource
NEPT-T
SELL
Jun 15, 2012
(Mark Call Minute.) Has been a concept stock for a long period of time. Had a big run here but still no earnings.
$3.910
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
SHORT
For years NEPT was in partnerships where they were extracting Omega-3 oils from krill oil and selling that to consumers. Now they're taking that extraction technology and applying it to the cannabis oil market. He's in a wait-and-see spots. The fundamentals don't back the move up in the stock. He has a small short on this.